Results 21 to 30 of about 4,040 (201)

In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria

Antibiotics, 2023
Background: Despite the availability of new options (ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam and cefiderocol), it is still very difficult to treat infections caused by metallo-β-lactamase (MBLs)-producers resistant to aztreonam.
Cécile Emeraud, Sandrine Bernabeu, Laurent Dortet   +2 more
doaj   +1 more source

In vitro activity of new combinations of β-lactam and β-lactamase inhibitors against the Mycobacterium tuberculosis complex

Microbiology Spectrum, 2023
As meropenem-clavulanic acid is recommended for the treatment of drug-resistant tuberculosis, the repurposing of new carbapenem combinations may provide new treatment options, including oral alternatives.
Elin Economou Lundeberg, Viktoria Andersson, Maria Wijkander, Ramona Groenheit, Mikael Mansjö, Jim Werngren, Teresa Cortes, Ivan Barilar, Stefan Niemann, Matthias Merker, Claudio U. Köser, Lina Davies Forsman   +11 more
doaj   +1 more source

Potency of Meropenem-Vaborbactam in Lung Surfactant [PDF]

Antimicrobial Agents and Chemotherapy, 2018
ABSTRACT This study investigated whether pulmonary surfactant has an effect on the in vitro antibacterial activity of either meropenem alone or meropenem in combination with vaborbactam at a fixed concentration of 8 μg/ml against several Klebsiella pneumoniae carbapenemase (KPC ...
Debora, Rubio-Aparicio, Jeff, Loutit, Michael, Dudley, Olga, Lomovskaya   +3 more
openaire   +2 more sources

Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections [PDF]

Journal of Clinical Medicine, 2019
This study reports the integrated analysis of two phase III studies of meropenem-vaborbactam in the treatment of acute bacterial infections. Targeting Antibiotic Non-Susceptible Gram-Negative Organisms (TANGO) I compared the clinical efficacy and tolerability of meropenem-vaborbactam and piperacillin-tazobactam in the treatment of complicated urinary ...
Chih-Cheng Lai, Chi-Chung Chen, Hung-Jen Tang   +2 more
openaire   +3 more sources

New evidence in severe pneumonia: meropenem-vaborbactam

Revista Española de Quimioterapia, 2022
The appearance and spread of new mechanisms of bacterial resistance to antibiotics is a serious health problem. One of the most difficult resistance mechanisms to treat is the production of carbapenemases. Carbapenemase KPC is one of those mechanisms with few therapeutic options.
Forteza Guillot, Maria, Martin Cerezuela, Maria, Ramirez, Paula   +2 more
openaire   +3 more sources

Global shortage of neonatal and paediatric antibiotic trials: rapid review. [PDF]

, 2017
OBJECTIVES: There have been few clinical trials (CTs) on antibiotics that inform neonatal and paediatric drug labelling. The rate of unlicensed and off-label prescribing in paediatrics remains high.
Barker, CI, Bielicki, JA, Bradley, JS, Folgori, L, Lutsar, I, Sharland, M, Thompson, G   +6 more
core   +4 more sources

Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against KPC-Producing K. pneumoniae Collected from Bacteremic Patients, 2018 to 2020 [PDF]

, 2022
The management of KPC-producing K. pneumoniae (KPC-Kp) in bloodstream infections (BSIs) represent a serious clinical challenge. In this study, the aim is to assess the incidence of resistance to novel β-lactams-β-lactamase inhibitor combinations (βL ...
Ambretti S, Bovo F, Gaibani P., Lazzarotto T, Lombardo D   +4 more
core   +1 more source

Management of KPC-Producing Klebsiella pneumoniae Infections [PDF]

, 2015
Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-KP) has become one of the most important contemporary pathogens, especially in endemic ...
M. Bassetti, D.R. Giacobbe, H. Giamarellou, C. Viscoli, G.L. Daikos, G. Dimopoulos, F.G. De Rosa, E.J. Giamarellos-Bourboulis, G.M. Rossolini, E. Righi, I. Karaiskos, M. Tumbarello, D.P. Nicolau, P.L. Viale, G. Poulakou, Rossolini, Munoz-Price, Grundmann, Maltezou, Giacobbe, Banerjee, Girmenia, Patel, Bauer, Arena, Kostrzewa, Rotova, Gaibani, Hoyos-Mallecot, Salimnia, Vincent, Arena, Paul, Zusman, Dickstein, Tzouvelekis, Tumbarello, Tumbarello, Daikos, Gutiérrez-Gutiérrez, Del Bono, Pea, Tenover, Clinical and Laboratory Standards Institute (CLSI), Nation, Capone, Monaco, Giacobbe, Giamarellou, Spyropoulou, Meletis, Karaiskos, Karaiskos, Sorlí, Sandri, Nation, Gonzalez-Padilla, Machuca, Stankowicz, Poulakou, Bassetti, Montravers, Bassetti, Ramirez, Wiskirchen, Giamarellou, Pontikis, Parker, Albiero, Lepak, Docobo-Pérez, Grabein, Shields, Temkin, Shields, Shields, Perez, Bulik, Giamarellou, Souli, Oliva, Cprek, Poulakou, Lu, Karvouniaris, Kollef, Rello, Solé-Lleonart, Palmer, Kalil, Monogue, Berthoin, Pea, Lorente, Ho, Kim, Keel, Martínez, Patel, Zarkotou, Falcone, Nguyen, de Oliveira, Dimopoulos, Chastre, Capellier, Havey, Matthaiou, Tacconelli, De Rosa, Sypsa, Gagliotti, Lin, Giacobbe, Munoz-Price, Tofteland, Schwaber, Lerner, De Rosa, Abdallah, Tumbarello, Giannella, Giannella, Giacobbe, Salsano, Sbrana, Girmenia, De Rosa, Forcina, Viale, Zuckerman, Saidel-Odes, Lübbert, Tascini, Oren, Tascini, Machuca, Bassetti, Falagas, Sutcliffe, Connors, Zhang, Solomkin   +142 more
core   +2 more sources

Safety evaluation of current therapies for high-risk severely ill patients with carbapenem-resistant infections [PDF]

, 2021
Introduction Infections due to carbapenem-resistant Gram-negative bacteria (CR-GNB) are increasingly frequent events, which are associated with a high mortality rate.
Bassetti, Matteo, Cenderello, Giovanni, Falletta, Antonio, Giacobbe, Daniele R., Vena, Antonio   +4 more
core   +1 more source

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections

International Journal of Infectious Diseases, 2021
Background: The limited armamentarium against multidrug-resistant Gram-negative bacilli led to the development of a new generation of β-lactam/β-lactamase inhibitor combinations (BL/BLI).
Helio S. Sader, Mariana Castanheira, Leonard R. Duncan, Rodrigo E. Mendes   +3 more
doaj   +1 more source